Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Colman

Showing results (61-70 of 155) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastomaChristopher E Pelloski, Anita Mahajan, Moshe Maor, et al.
Neurosurgery|October 26, 2012
ELTD1, a potential new biomarker for gliomasRheal A Towner, Randy L Jensen, Howard Colman, et al.
Cancer Medicine|October 24, 2024
The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort studyDominik J Ose, Emmanuel Adediran, Bayarmaa Mark, et al.
Cancer|May 2, 2013
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastomaShlomit Yust-Katz, Diane Liu, Ying Yuan, et al.
Molecular Cancer Therapeutics|January 8, 2010
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathwayJun Wei, Jason Barr, Ling-Yuan Kong, et al.
Acta Neuropathologica|September 28, 2018
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV"Daniel J Brat, Kenneth Aldape, Howard Colman, et al.
Cancer Research|March 9, 2005
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastomaJanice M Nigro, Anjan Misra, Li Zhang, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant linesDylan J Keiser, Meghan S Buddy, Solmaz Mojarad-Jabali, et al.
Cell Reports. Medicine|February 8, 2025
Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastasesJared Almazan, Tursun Turapov, David A Kircher, et al.
Stem Cells (Dayton, Ohio)|September 17, 2013
A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cellsNorihiko Saito, Jun Fu, Siyuan Zheng, et al.
Pageof 16

Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastomaChristopher E Pelloski, Anita Mahajan, Moshe Maor, et al.
Neurosurgery|October 26, 2012
ELTD1, a potential new biomarker for gliomasRheal A Towner, Randy L Jensen, Howard Colman, et al.
Cancer Medicine|October 24, 2024
The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort studyDominik J Ose, Emmanuel Adediran, Bayarmaa Mark, et al.
Cancer|May 2, 2013
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastomaShlomit Yust-Katz, Diane Liu, Ying Yuan, et al.
Molecular Cancer Therapeutics|January 8, 2010
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathwayJun Wei, Jason Barr, Ling-Yuan Kong, et al.
Acta Neuropathologica|September 28, 2018
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV"Daniel J Brat, Kenneth Aldape, Howard Colman, et al.
Cancer Research|March 9, 2005
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastomaJanice M Nigro, Anjan Misra, Li Zhang, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant linesDylan J Keiser, Meghan S Buddy, Solmaz Mojarad-Jabali, et al.
Cell Reports. Medicine|February 8, 2025
Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastasesJared Almazan, Tursun Turapov, David A Kircher, et al.
Stem Cells (Dayton, Ohio)|September 17, 2013
A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cellsNorihiko Saito, Jun Fu, Siyuan Zheng, et al.
Pageof 16